CENTER FOR DRUG EVALUATION AND RESEARCH

Approval Package for:

APPLICATION NUMBER:
NDA 20-699/S-010

Name: Effexor XR Extended-Release Capsules

Generic Name: venlafaxine hydrochloride

Sponsor: Wyeth Pharmaceuticals Inc.

Approval Date: 03/09/2000
APPLICATION NUMBER:
NDA 20-699/S-010

CONTENTS

<table>
<thead>
<tr>
<th>Reviews / Information Included in this Review</th>
</tr>
</thead>
<tbody>
<tr>
<td>Approval Letter</td>
</tr>
<tr>
<td>Approvable Letter(s)</td>
</tr>
<tr>
<td>Labeling</td>
</tr>
<tr>
<td>Medical Review(s)</td>
</tr>
<tr>
<td>Chemistry Review(s)</td>
</tr>
<tr>
<td>EA/FONSI</td>
</tr>
<tr>
<td>Pharmacology Review(s)</td>
</tr>
<tr>
<td>Statistical Review(s)</td>
</tr>
<tr>
<td>Microbiology Review(s)</td>
</tr>
<tr>
<td>Clinical Pharmacology/Biopharmaceutics Review(s)</td>
</tr>
<tr>
<td>Administrative and Correspondence Document(s)</td>
</tr>
</tbody>
</table>
APPLICATION NUMBER:
NDA 20-699/S-010

APPROVAL LETTER
Wyeth Laboratories, Inc.
Attention: Patricia Foti Mann
Manager, marketed products U.S. Technical Regulatory Affairs
P. O. Box 8299
Philadelphia, PA 19101-8299

Dear Ms. Mann:

Please refer to your supplemental new drug application dated October 6, 1999, received October 7, 1999, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Effexor XR (venlafaxine hydrochloride) Extended Release Capsules, 37.5 mg, 75 mg, 100 mg, and 150 mg.

This "Changes Being Effected in 30 days" supplemental new drug application provides for an alternate release and stability testing facility for Effexor XR (venlafaxine hydrochloride) Extended Release Capsules, 37.5 mg, 75 mg, 100 mg, and 150 mg.

We have completed the review of this supplemental application and it is approved.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call Paul David, R.Ph., Regulatory Management Officer, at (301) 594-2850.

Sincerely,

Robert H. Seevers, Ph.D.
Chemistry Team Leader, Psychiatric Drugs for the Division of Neuropharmacological Drug Products, (HFD-120)
DNDC I, Office of New Drug Chemistry Center for Drug Evaluation and Research

cc:
Archival NDA 20-699
CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:
NDA 20-699/S-010

CHEMISTRY REVIEW(S)
1. ORGANIZATION: HFD-120
2. NDA Number: 20-699
3. SUPPLEMENT NUMBERS/DATES: SCM-010
   Letter date: October 6, 1999
   Stamp date: October 7, 1999
4. AMENDMENTS/REPORTS/DATES: None
5. RECEIVED BY CHEMIST: October 14, 1999

6. APPLICANT NAME & ADDRESS
   Wyeth Laboratories, Inc.
   P. O. Box 8299
   Philadelphia, PA 19101-8299

7. NAME OF DRUG:
   Effexor® XR Extended Release Capsules

8. NONPROPRIETARY NAME:
   venlafaxine hydrochloride

9. CHEMICAL NAME/STRUCTURE:
   \[(R/S)-1-[(2-dimethylamino)-1-(4-methoxyphenyl)ethyl] cyclohexanol hydrochloride\]

10. DOSAGE FORM(S):
    Extended Release Capsules

11. POTENCY:
    37.5mg, 75mg, 100mg, 150mg

12. PHARMACOLOGICAL CATEGORY:
    Treatment of Depression and Generalized Anxiety Disorder

13. HOW DISPENSED:
    \[\begin{array}{ccc}
    & X & (R_x) \\ X & Yes & No \\
    \end{array}\]

14. RECORDS & REPORTS CURRENT:
    REVIEW RECORDS & REPORTS CURRENT
    \[\begin{array}{ccc}
    & X & Yes \\ X & Yes & No \\
    \end{array}\]

15. RELATED IND/NDA/DMF:
    DMF

16. SUPPLEMENT PROVIDES FOR: An alternate release and stability testing facility for Effexor® XR
    (venlafaxine hydrochloride) Extended Release Capsules, 37.5 mg, 75 mg, 100 mg, and 150 mg.

17. COMMENTS:
    NDA 20-699 Supplement SCM-010 (dated October 6, 1999) is submitted, along with three attachments,
    in accordance with 21 CFR 314.70(a), and FDA Guidance for Industry entitled PAC-ATLS: Post-
    Approval Changes-Analytical Testing Laboratory Sites, published April 1998. This supplemental
    amendment will be implemented 30 days from the date of this submission.

    Supplement SCM-010 provides the following documentation required of a PAC-ATLS CBE supplement
    as outlined in FDA Guidance for Industry PAC-ATLS: Postapproval Changes-Analytical Testing
    Laboratory Sites, published in April 1998.
1) A commitment from Ayerst Laboratories to use the same test methods as currently approved in the application (Supplement SCM-10, Attachment 2).

2) Certification that the proposed alternate release and stability testing facility (i.e., Ayerst Laboratories Division of Wyeth-Ayerst Pharmaceuticals, Inc., Rouses Point, NY) has a current and satisfactory cGMP compliance status for the type of testing performed, based on an inspection concluded by the FDA’s buffalo District Office in January 1997 and subsequent inspections in 1997 and 1998 (Supplement SCM-010, Attachment 3).

3) Ayerst Laboratories confirmation that all post-approval commitments made by Ayerst Laboratories relating to the test methods have been fulfilled, and that the proposed alternate release and stability testing facility has the capability to perform the intended testing.

Supplement SCM-010 includes a revised copy of NDA 20-699 Section II.D. Drug Product-Manufacturer, Packaging, Testing, and Release Facilities (Supplement SCM-010, Attachment 1), revised July 14, 1999 to replace the corresponding page dated May 11, 1999. The revised Section adds the statement that drug product can also be tested, for release and stability at Ayerst Laboratories, Division of Wyeth-Ayerst Pharmaceuticals, Inc., Rouses Point, NY.

A site inspection was requested on January 21, 2000 for the proposed alternate release and stability testing facility (i.e., Ayerst Laboratories, Division of Wyeth-Ayerst Pharmaceuticals, Inc., Rouses Point, NY). The Office of Compliance (OC) found the proposed alternate release and stability testing facility acceptable (based on profile) on February 1, 2000.

18. CONCLUSIONS & RECOMMENDATIONS:
This submission meets the criteria of a PAC-ATLS CBE supplement. On February 1, 2000 the proposed alternate release and stability testing facility (i.e., Ayerst Laboratories Division of Wyeth-Ayerst Pharmaceuticals, Inc., Rouses Point, NY) received an over all acceptable recommendation from OC for finished dosage release tester and finished dosage stability tester of Effexor® XR (venlafaxine hydrochloride) Extended release Capsules, 37.5 mg, 75 mg, 100 mg, and 150 mg. Recommend issuing approval letter.

19. REVIEWER NAME

Lorenzo A. Rocca

18/9/00

20. TEAM LEADER NAME

Robert H. Seever

DATE COMPLETED

3/9/00

DATE COMPLETED

3/9/00

cc:
NDA 20-699/SCM010
HFD-120/Division File
HFD-120/RSeevers
HFD-120/LRocca

by: LRocca, File: C:\LR\Supplement\n20699\Scm-010Review.doc
CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:
NDA 20-699/S-010

ADMINISTRATIVE and
CORRESPONDENCE DOCUMENTS
NDA 20-699/S-010

Wyeth-Ayerst Laboratories
P.O. Box 8299
Philadelphia, PA 19101-8299

Attention: Patricia Foti Mann
Manager, Marketed Products
U.S. Technical Regulatory Affairs

Dear Ms. Mann:

We acknowledge receipt of your supplemental application for the following:

Name of Drug: Effexor (venlafaxine hydrochloride) Extended Release Capsules

NDA Number: 20-699
Supplement Number: 010

Date of Supplement: 06-Oct-99
Date of Receipt: 07-Oct-99

Unless we find the application not acceptable for filing, this application will be filed under Section 505(b)(1) of the Act on 06-Dec-99 in accordance with 21 CFR 314.101(a).

All communications concerning this NDA should be addressed as follows:

Center for Drug Evaluation and Research
Division of Neuropharmacological Drug Products, HFD-120
Office of Drug Evaluation I
Attention: Document Control Room 4008
5600 Fishers Lane
Rockville, MD 20857

Sincerely,

[Signature]

John S. Purvis
Chief, Project Management Staff
Division of Neuropharmacological Drug Products, HFD-120
Office of Drug Evaluation I
Center for Drug Evaluation and Research
cc:
    Original NDA 20-699/010
    HFD-120/Div. Files
    HFD-120/CSO/David

filename:

SUPPLEMENT ACKNOWLEDGEMENT
Effexor® XR (venlafaxine hydrochloride) Extended Release Capsules  
NDA No. 20-699

Russell G. Katz, M.D., Director  
Division of Neuropharmacological Drug Products, HFD-120  
Center for Drug Evaluation and Research  
Food and Drug Administration  
Attn: Document Control Room 4008, 4th floor  
1451 Rockville Pike  
Rockville, MD 20852  

PAC-ATLS SPECIAL SUPPLEMENT - CHANGES BEING EFFECTED

Dear Dr. Katz:

Reference is made to Wyeth Laboratories New Drug Application No. 20-699 for Effexor® XR (venlafaxine hydrochloride) Extended Release Capsules, 37.5 mg, 75 mg, 100 mg, and 150 mg.

In accordance with 21 CFR 314.70(a) and FDA’s Guidance for Industry: “PAC-ATLS: Post-Approval Changes – Analytical Testing Laboratory Sites”, we are filing this supplemental application to provide for Ayerst Laboratories Division of Wyeth-Ayerst Pharmaceuticals, Inc., 64 Maple Street, Rouses Point, New York, as an alternate release and stability testing facility for this product. Currently, Wyeth Pharmaceuticals Company, State Road No. 3, Guayama, Puerto Rico, is the approved release and stability testing facility. This change will be implemented thirty days from the date of this submission.

We confirm that this submission meets the following four criteria of a PAC-ATLS CBE supplement: (1) The test methods approved in the new drug application or methods implemented under 21 CFR 314.70(d) are used at the intended facility; (2) All post-approval commitments made by the applicant relating to the test methods have been fulfilled; (3) The proposed facility has the capability to perform the intended testing; (4) The proposed facility has had a satisfactory current good manufacturing practice (cGMP) inspection within the past two years.

In support of this submission, we provide the following:

Attachment 1: Revised Section II.D. Drug Product – Manufacturer(s)

Attachment 2: A commitment from Ayerst Laboratories to use the same test methods as currently approved in the application.
Attachment 3: Written certification from the Rouses Point, New York facility stating that it has a current and satisfactory cGMP compliance status for the type of testing performed, based on an inspection concluded by the FDA’s Buffalo District Office in January 1997 and subsequent inspections in 1997 and 1998.

Please note that Ayerst Laboratories Division of Wyeth-Ayerst Pharmaceuticals and Wyeth Pharmaceuticals Company, which are referenced in this submission, are all corporate entities of American Home Products Corporation.

As per 21 CFR 314.71(b), Wyeth-Ayerst Laboratories hereby certifies that a complete copy of the supplement has been forwarded as a Field Copy to the FDA District Office at the address below:

Mr. John Podsadowski
Program Coordinator for Field Copy Submissions
Buffalo District
Food and Drug Administration
599 Delaware Avenue
Buffalo, New York 14202

To assist the Agency’s administrative coordination of this supplement, we also have provided a copy of the supplement’s cover letter to the FDA Home District Office for Wyeth-Ayerst Laboratories located in Philadelphia, PA.

We trust that you will find this supplement satisfactory and that it will be approved at your earliest convenience. If you have any questions, please contact the undersigned at (610) 902-3727 or Ms. Sandra Freer at (610) 902-3797.

Sincerely,


defayratry
Patricia Foti Mann
Manager, Marketed Products
U.S. Technical Regulatory Affairs

Cover letter w/o attachments
cc Ms. Debra Pagano
Program Coordinator for Field Copy Submissions
Department of Health and Human Services
Food and Drug Administration
2nd and Chestnut Streets
Philadelphia, PA 19101-2973